147.00

EFFICIENCY OF THE MODERN COMBINED DRUGS IN COMPLEX TREATMENT OF THE ASTHMATIC CHILDREN

J.G. Levina, L.S. Namazova, K.E. Efendieva, N.I. Voznesenskaja, R.M. Torshhoeva, V.A. Barannik Ambulatory Medicine, Scientific Centre of Children Health, Moscow, Russia <u>doctor_clew@mail.ru</u>

Aim: to estimate efficiency of combined drug (Simbicort) in complex treatment of children suffering moderate and severe asthma.

Methods: examination of 30 patients (10-18 y.o.) suffering of moderate and severe bronchial asthma in the exacerbation period and 1-3 months after. 26 boys and 4 girls received one or two Simbicort (160/4,5 mcg) inhalations b.d.: group A 22 boys and 4 girls with severe persistent asthma, group B 4 boys with moderate persistent asthma. The following factors were considered: spyrography data, PEF data, number of breathlessness, the physical data of bronchoobstruction, tachycardia episodes, immune response parameters (cytokine status).

Results: the following observations were made: decrease of dyspnoea episodes (was estimated on a standard ball scale) from 5,5 to 0 balls (p<0,01), increase of spirografy parameters and individual peakflowmetry for 40%, decrease of frequency of heart bits and breathing to normal parameters, improvement of physical data. The treatment did not require involvement of oral theophyllin and systematic steroids, inhalations of β 2-agonists (Ventolinum). The clinical efficiency of the therapy was accompanied by positive changes of the immune status (decreasing of synthesis of proinflammatory cytocines IL-1, FNO-a, IL-6 and increasing of production of anti-inflammatory mediators).

Conclusion: the combined therapy by modern drugs proved to be efficient, safe and patogenetically confirmed treatment of non-poor-controlled moderate and severe bronchial asthma suffered by children.